Published peptide research references
Lanreotide
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
Le Wang, Shenglin Chen, Mengying Wu, Lijuan Zhou · Scientific reports · 2025
Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.
Yankun Li, Yue Han, Peng Gao · Endocrine · 2025
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz · JCO oncology practice · 2022
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Anja Rinke, Christoph Maintz, Lothar Müller, Matthias M Weber, Harald Lahner, Marianne Pavel, Wolfgang Saeger, Aude Houchard, Hanna Ungewiss, Stephan Petersenn · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2021
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu, LANTERN study investigators · BMC endocrine disorders · 2020
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Marianne E Pavel, Alexandria T Phan, Edward M Wolin, Beloo Mirakhur, Nilani Liyanage, Susan Pitman Lowenthal, George A Fisher, Aaron I Vinik, CLARINET Study Investigators · The oncologist · 2019
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
Rene M M van Aerts, Wietske Kievit, Hedwig M A D'Agnolo, Charles J Blijdorp, Niek F Casteleijn, Shosha E I Dekker, Johan W de Fijter, Maatje van Gastel, Tom J Gevers, Liyanne F M van de Laarschot, Marten A Lantinga, Monique Losekoot · Gastroenterology · 2019
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Esther Meijer, Folkert W Visser, Rene M M van Aerts, Charles J Blijdorp, Niek F Casteleijn, Hedwig M A D'Agnolo, Shosha E I Dekker, Joost P H Drenth, Johan W de Fijter, Maatje D A van Gastel, Tom J Gevers, Marten A Lantinga · JAMA · 2018
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik, ELECT Study Investigators · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2018
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks · The oncologist · 2017
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley · Endocrine-related cancer · 2016
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Aaron I Vinik, Edward M Wolin, Nilani Liyanage, Edda Gomez-Panzani, George A Fisher, ELECT Study Group * · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
Philippe J Caron, John S Bevan, Stephan Petersenn, Aude Houchard, Caroline Sert, Susan M Webb, PRIMARYS Investigators Group · Pituitary · 2016
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2016
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley · The New England journal of medicine · 2014
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Mônica R Gadelha, Marcello D Bronstein, Thierry Brue, Mihail Coculescu, Maria Fleseriu, Mirtha Guitelman, Vyacheslav Pronin, Gérald Raverot, Ilan Shimon, Kayo Kodama Lievre, Juergen Fleck, Mounir Aout · The lancet. Diabetes & endocrinology · 2014
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Philippe J Caron, John S Bevan, Stephan Petersenn, Daniel Flanagan, Antoine Tabarin, Gaëtan Prévost, Pascal Maisonobe, Antoine Clermont, PRIMARYS Investigators · The Journal of clinical endocrinology and metabolism · 2014
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Akira Shimatsu, Akira Teramoto, Naomi Hizuka, Kazuo Kitai, Joaquim Ramis, Kazuo Chihara · Endocrine journal · 2013
Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Gherardo Mazziotti, Andrea Giustina · Pituitary · 2010
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck, Martijn G H van Oijen, Aswin L Hoffmann, Helena M Dekker, Robert A de Man, Joost P H Drenth · Gastroenterology · 2009
Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
Iñaki F Trocóniz, Josep-María Cendrós, Concepción Peraire, Joaquim Ramis, Maria J Garrido, Paolo F Boscani, Rosendo Obach · Clinical pharmacokinetics · 2009
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
T Lucas, R Astorga, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly · Clinical endocrinology · 2006
Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
Joseph M Cendros, Concepción Peraire, Iñaki Fernández Trocóniz, Rossend Obach · Metabolism: clinical and experimental · 2005
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Ph Caron, A Beckers, D R Cullen, M I Goth, B Gutt, P Laurberg, A M Pico, M Valimaki, W Zgliczynski · The Journal of clinical endocrinology and metabolism · 2002
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
P Chanson, V Boerlin, C Ajzenberg, Y Bachelot, P Benito, J Bringer, P Caron, B Charbonnel, C Cortet, B Delemer, F Escobar-Jiménez, L Foubert · Clinical endocrinology · 2000